(Q41630422)

5 October 2017

1 reference

title

Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs (English)

1 reference

5 October 2017

1 reference

P R Kowey

1

1 reference

5 October 2017

R A Marinchak

series ordinal

2

1 reference

5 October 2017

S J Rials

series ordinal

3

1 reference

5 October 2017

D Bharucha

series ordinal

4

1 reference

5 October 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

American Journal of Cardiology

5 October 2017

published in

1 reference

5 October 2017

volume

80

1 reference

5 October 2017

issue

8A

1 reference

5 October 2017

page(s)

16G-23G

1 reference

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Pharmacology, pharmacodynamics and pharmacokinetics of sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Hemodynamic studies with sotalol in man, performed at rest, during exercise, and during right ventricular pacing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Concentration/response relations for the multiple antiarrhythmic actions of sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Electromechanical characterization of the effects of racemic sotalol and its optical isomers on isolated canine ventricular trabecular muscles and Purkinje strands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Efficacy of ibutilide for termination of atrial fibrillation and flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Electrophysiology and pharmacology of ibutilide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Class III antiarrhythmic action and inotropy: effects of dofetilide in acute ischemic heart failure in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Bretylium tosylate in the treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Bretylium tosylate for suppression of induced ventricular fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Bretylium: a prototype for future development of antidysrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

The effect of bretylium on intracellular cardiac action potentials in relation to its anti-arrhythmic and local anaesthetic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Amiodarone pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Drug interactions with amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Amiodarone dosing: a proposal based on its pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900710-8

10.1016/S0002-9149(97)00710-8

7 January 2021

Identifiers

DOI

1 reference

5 October 2017

1 reference